Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease.
Melissa A Calton, Roxanne H Croze, Theodore H Sullivan...
https://pubmed.ncbi.nlm.nih.gov/41124321/Actively Recruiting
Led by 4D Molecular Therapeutics · Updated on 2026-07-06
30
Participants Needed
20
Research Sites
208 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.
CONDITIONS
4D-710 in Adult Patients With Cystic Fibrosis
4
4DMT Patient Advocacy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
4D Molecular Therapeutics
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 4D-710 Gene Therapy (Investigational) | Current Standard Care (Guideline-Based) |
|---|---|---|
| What is it? | An investigational aerosolized gene therapy that delivers a modified CFTR gene (CFTRΔR) to airway cells using an AAV vector (4D-A101). Designed to address dysfunctional or absent CFTR protein in adults with cystic fibrosis lung disease. | A tailored combination of mucolytics, airway clearance, pulmonary therapies, infection prevention, and where eligible, CFTR modulator drugs. Supportive care, nutritional and psychosocial support are mainstays for those not eligible for or intolerant of modulators. |
| Primary Use / Intended Benefit | Being studied for the potential to restore airway CFTR function in adults whose CF lung disease is inadequately addressed by, or who cannot take, current modulator therapies. | To maximize lung function, prevent infection, and alleviate symptoms through personalized regimens including modulator therapy when clinically indicated, or best supportive care otherwise. |
| How is it given or performed? | Delivered to the lungs by aerosol inhalation in a clinical setting, as a single dose during the trial. Sub-study participants continue their background modulator therapy. | CFTR modulators, when used, are typically oral daily medications. Airway clearance techniques (such as chest physiotherapy), inhaled mucolytics and antibiotics, and regular monitoring are the backbone of all care regimens. |
| Evidence Status | Early-phase clinical study; efficacy and safety in humans not yet established. No published patient outcome data at this time. | Robust evidence supports improved lung function, reduced exacerbations, and extended life expectancy with current CFTR modulators for eligible patients. Best supportive care has known symptomatic and infection-prevention benefits, but is less effective than modulator therapy. |
| Important Limitations | Long-term safety, durability, and effectiveness have not been established. Only adults are eligible; prior gene therapy is exclusionary, and background disease variability may affect response. | CFTR modulators benefit only patients with eligible genotypes. Drug intolerance and lack of access limit their use in some patients. Best supportive care does not address underlying CFTR dysfunction. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Variable duration during Phase 1
Participants who cannot use CFTR modulator therapy receive various dose levels of the gene therapy 4D-710 to find the recommended dose for further study.
Duration - Variable duration during Phase 2
Participants receive a single inhaled dose of 4D-710 at the selected dose level for further evaluation.
Duration - Variable duration during Sub-Study
Participants on stable CFTR modulator therapy receive various doses of 4D-710 to assess safety and early effects.
Duration - Up to 60 months
Participants are monitored for adverse events and lung health for up to 60 months after treatment.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Melissa A Calton, Roxanne H Croze, Theodore H Sullivan...
https://pubmed.ncbi.nlm.nih.gov/41124321/4D Molecular Therapeutics
Lead Sponsor